Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2022-10-10
2037-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of the Tumor Microenvironment in Aggressive Meningiomas
NCT05821790
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
NCT06036706
Meningioma and Embolism Thrombosis Risk & Investigation of Coagulation
NCT06709833
Multicenter Evaluation in Patients With MEningiomas of the Response to Treatment With 177LUTEtium-oxodotreotide
NCT06255249
Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients
NCT05990556
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endovascular embolization
Endovascular embolization
Therapeutic endovascular embolization in general anesthesia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endovascular embolization
Therapeutic endovascular embolization in general anesthesia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indication for treatment due to growth, symptoms or both
* Tumor location suggestive of vascular supply via middle meningeal artery branches
* Age 18 years or older
* Karnofsky performance status of 90 or better (able to carry on normal activity and work)
Exclusion Criteria
* Previously treated for meningioma
* Intraosseous growth
* Tumor related brain edema
* Neurofibromatosis type 2
* Systemic cancer
* Epilepsy
* Progressive neurodegenerative disorder (eg. MS, Parkinsons disease)
* History of psychiatric disorder
* Unfit for participation for any other reason judged by the physician including patients
* Contraindications to MRI
* Allergic to contrast agents
* Relative contraindications to endovascular treatment judged from CT angiography (tortoise carotid arteries, carotid stenosis, calcified aortic arch, anatomical vascular variants/anomalies suggesting increased risk with endovascular treatment)
* DSA (Digital subtraction angiography) from carotid artery suggesting that significant vascular supply is from other vessels than the MMA.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Olavs Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ole Solheim, PhD
Role: PRINCIPAL_INVESTIGATOR
St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Olavs Hospital
Trondheim, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ole Solheim, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
392999
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.